Paul Hartmann AG vs. Attends Healthcare Products: Federal Circuit Vacates PTAB Ruling in Incontinence Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Paul Hartmann AG v. Attends Healthcare Products, Inc. |
| Case Number | 22-1727 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from PTAB |
| Duration | Apr 2022 – Mar 2024 1 year 11 months |
| Outcome | Vacated & Remanded |
| Patents at Issue | |
| Accused Products | Absorbent Incontinence Articles |
Case Overview
The Parties
⚖️ Plaintiff (Patent Holder)
Germany-based global leader in medical and hygiene products, with an extensive IP portfolio covering wound care, incontinence solutions, and infection management.
🛡️ Defendant (Petitioner)
U.S.-based manufacturer of incontinence care products, directly competing in the market segment protected by Hartmann’s patent.
Patents at Issue
This landmark case involved U.S. Patent No. 8,708,990 B2, covering an absorbent incontinence article featuring an improved closure system. The patent protects design and functional innovations in how incontinence products secure to the wearer, a feature with substantial commercial and clinical value. These utility patents are registered with the U.S. Patent and Trademark Office (USPTO) and protect functional technology.
- • US 8,708,990 B2 — Absorbent incontinence article with improved closure system
Developing absorbent incontinence products?
Check if your product design might infringe this or related patents before launch.
The Federal Circuit’s Verdict & Legal Analysis
Outcome
The Federal Circuit issued a definitive procedural ruling: VACATED AND REMANDED. The Board’s prior decision—which had addressed the patentability of U.S. Patent No. 8,708,990 B2—was set aside, and the matter was returned to the PTAB for further proceedings consistent with the appellate court’s reasoning. No damages were awarded, as this was a validity proceeding rather than an infringement trial. No injunctive relief was at issue in the appellate record. The specific financial terms, if any, between the parties remain undisclosed.
Key Legal Issues
The Federal Circuit’s analysis focused on patentability—specifically, whether the PTAB correctly evaluated the validity of Hartmann’s patent claims through the invalidity/cancellation framework. The court’s decision to vacate indicates that the Board committed a reversible legal or procedural error in its analysis. This ruling has significant implications for how PTAB invalidity rulings are scrutinized on appeal in the consumer medical goods sector.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in absorbent incontinence article design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 47 related patents in this technology space
- See which companies are most active in incontinence IP
- Understand claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Absorbent article closure systems
47 Related Patents
In incontinence technology space
Design-Around Options
Available for most claims
✅ Key Takeaways
Federal Circuit vacatur of PTAB invalidity rulings remains an effective appellate tool when Board reasoning is legally deficient.
Search related case law →PTAB claim construction errors and incomplete reasoning are primary grounds for vacatur in AIA proceedings.
Explore precedents →Frequently Asked Questions
U.S. Patent No. 8,708,990 B2 (Application No. 13/861,341), covering an absorbent incontinence article with an improved closure system.
The court found sufficient legal error in the Board’s patentability analysis to warrant vacatur and remand for reconsideration, though the specific doctrinal basis reflects the court’s ongoing enforcement of rigorous PTAB reasoning standards.
It reinforces that IPR invalidity rulings are not final until affirmed on appeal, and that patent holders with meritorious claims should invest in appellate review when PTAB decisions appear procedurally defective.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Court of Appeals for the Federal Circuit — Case 22-1727
- U.S. Patent and Trademark Office — Patent Center (Patent No. 8,708,990 B2)
- USPTO Patent Trial and Appeal Board (PTAB) Portal
- PACER Case No. 22-1727
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.